Cambridge Healthtech Institute’s 5th Annual

Next-Generation Immunotherapies

In vivo CAR T Engineering, New Targets, and Beyond

May 14-15, 2026

 

The immunotherapy field has achieved extraordinary breakthroughs in recent years, yet major challenges remain in targeting, delivery, and efficacy. Cambridge Healthtech Institute’s 5th annual Next-Generation Immunotherapies conference will spotlight the latest wave of immune reprogramming platforms—from in vivo CAR T engineering and AI/ML-driven design to targeting dark antigens, novel cancer therapies, genome editing, and emerging delivery technologies. Join leading experts as they share cutting-edge strategies poised to transform cancer and autoimmune treatment.

 

Coverage will include, but is not limited to:

 

In vivo Engineering of the Immune System: CAR T and Beyond

  • Latest developments in in vivo CAR T—clinical and preclinical updates
  • Therapeutic area applicability: Oncology, autoimmune diseases and regenerative medicine
  • Comparing viral (lenti) vs. RNA platforms—what do the recent acquisitions and collabs tell us
  • Next-generation in vivo engineering and delivery beyond CAR T payloads (PD-1s)
  • Engineering strategies to improve specificity and reduce off-target toxicity
  • Clinical, regulatory path, CMC, and commercial considerations

Next Generation Immunotherapies

  • Advances in mRNA cancer therapes
  • Cancer vaccines in combination with CAR T
  • Oncolytic viruses
  • Novel delivery methods
  • Oligonucleotides, RNAi conjugates
  • Nanomedicine
  • Latest advances in cancer vaccines
  • Updates from key players
  • Oncolytic Viruses—where is the industry going? What are the bottlenecks?

AI/ ML Approaches for Developing Next-Generation Immunotherapies

  • Genome screening for identifying new targets
  • Leveraging AI and machine learning to identify novel immunotherapy targets and MOAs
  • Computational engineering of antibody domains, TCE affinity, and CAR constructs for improved safety, persistence, and stability

Dark Genome Targeting and Discovery of New Immunotherapies

  • Illuminating the Dark Antigen Landscape: Next-Generation Strategies for Immunotherapy
  • Expanding Beyond Surface Antigens—Unlocking intracellular oncogenes and tumor suppressors through TCR-based and pHLA-targeting engagers.
  • Novel Target Discovery Platforms—Leveraging surfaceome profiling, multi-omics, and AI to identify underexplored immunotherapy targets.
  • Engineering for Specificity and Safety—Strategies to overcome HLA restriction, antigen escape, and off-tumor risks.
  • Translating Dark Antigens into Therapies—Case studies in KRAS, p53, and viral-driven cancers demonstrating clinical potential.

 

The deadline for priority consideration is October 17, 2025.

 

AAll proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

Opportunities for Participation:

 


For more details on the conference, please contact:

Daniel Barry

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+44) 7837-651-303

Email: dbarry@healthtech.com

 

For sponsorship information, please contact:

Companies A-K

Jason Gerardi

Sr. Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-5452

Email: jgerardi@healthtech.com

 

Companies L-Z

Ashley Parsons

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-1340

Email: ashleyparsons@healthtech.com


Submit a Speaker Proposal

View By:


Premier Sponsors

FairJourneyBiologics GenScript-CRO Integral-Molecular_NEW   Nona_Biosciences_NEW